Potential of imatinib mesylate as a novel treatment for pulmonary fibrosis

References

• Ryu JH, Daniels CE, Hartman TE, Yi ES. Diagnosis of interstitial lung diseases. Mayo Clin. Proc.82(8), 976–986 (2007).
   PubMedGoogle Scholar
• King TE Jr. Clinical advances in the diagnosis and therapy of the interstitial lung diseases. Am. J. Resp. Crit. Care Med.172(3), 268–279 (2005).
   PubMed Web of Science ®Google Scholar
• Bringardner BD, Baran CP, Eubank TD, Marsh CB. The role of inflammation in the pathogenesis of idiopathic pulmonary fibrosis. Antioxid. Redox Signal.10(2), 287–302 (2008).
   PubMed Web of Science ®Google Scholar
• Hunninghake GW, Schwarz MI. Does current knowledge explain the pathogenesis of idiopathic pulmonary fibrosis? A perspective. Proc. Am. Thorac. Soc.4(5), 449–452 (2007).
   PubMedGoogle Scholar
• Kim DS, Collard HR, King TE Jr. Classification and natural history of the idiopathic interstitial pneumonias. Proc. Am. Thorac. Soc.3(4), 285–292 (2006).
   PubMedGoogle Scholar
• Leslie KO. Historical perspective: a pathologic approach to the classification of idiopathic interstitial pneumonias. Chest128(5 Suppl. 1), 513S–519S (2005).
   Google Scholar
• Visscher DW, Myers JL. Histologic spectrum of idiopathic interstitial pneumonias. Proc. Am. Thorac. Soc.3(4), 322–329 (2006).
   PubMedGoogle Scholar
• Noth I, Martinez FJ. Recent advances in idiopathic pulmonary fibrosis. Chest132(2), 637–650 (2007).
   PubMed Web of Science ®Google Scholar
• Gotway MB, Freemer MM, King TE Jr. Challenges in pulmonary fibrosis. 1: use of high resolution CT scanning of the lung for the evaluation of patients with idiopathic interstitial pneumonias. Thorax62(6), 546–553 (2007).
   PubMed Web of Science ®Google Scholar
• Hyzy R, Huang S, Myers J, Flaherty K, Martinez F. Acute exacerbation of idiopathic pulmonary fibrosis. Chest132(5), 1652–1658 (2007).
   PubMed Web of Science ®Google Scholar
• Collard HR, Moore BB, Flaherty KR et al. Acute exacerbations of idiopathic pulmonary fibrosis. Am. J. Resp. Crit. Care Med.176(7), 636–643 (2007).
   PubMed Web of Science ®Google Scholar
• Maher TM, Wells AU, Laurent GJ. Idiopathic pulmonary fibrosis: multiple causes and multiple mechanisms? Eur. Respir. J.30(5), 835–839 (2007).
   PubMed Web of Science ®Google Scholar
• Keane MP, Strieter RM, Lynch JP 3rd, Belperio JA. Inflammation and angiogenesis in fibrotic lung disease. Sem. Resp. Crit. Care Med.27(6), 589–599 (2006).
   PubMedGoogle Scholar
• Pardo A, Selman M, Kaminski N. Approaching the degradome in idiopathic pulmonary fibrosis. Int. J. Biochem. Cell Biol.40(6–7), 1141–1155 (2008).
   PubMed Web of Science ®Google Scholar
• Scotton CJ, Chambers RC. Molecular targets in pulmonary fibrosis: the myofibroblast in focus. Chest132(4), 1311–1321 (2007).
   PubMed Web of Science ®Google Scholar
• Thannickal VJ, Horowitz JC. Evolving concepts of apoptosis in idiopathic pulmonary fibrosis. Proc. Am. Thorac. Soc.3(4), 350–356 (2006).
   PubMedGoogle Scholar
• Andersson-Sjoland A, de Alba CG, Nihlberg K et al. Fibrocytes are a potential source of lung fibroblasts in idiopathic pulmonary fibrosis. Int. J. Biochem. Cell Biol. DOI: 10.1016/j.biocel.2008.02.012 (2008) (Epub ahead of print).
   Google Scholar
• Willis BC, Liebler JM, Luby-Phelps K et al. Induction of epithelial–mesenchymal transition in alveolar epithelial cells by transforming growth factor-β1: potential role in idiopathic pulmonary fibrosis. Am. J. Pathol.166(5), 1321–1332 (2005).
   PubMed Web of Science ®Google Scholar
• Agostini C, Gurrieri C. Chemokine/cytokine cocktail in idiopathic pulmonary fibrosis. Proc. Am. Thorac. Soc.3(4), 357–363 (2006).
   PubMedGoogle Scholar
• Ask K, Martin GE, Kolb M, Gauldie J. Targeting genes for treatment in idiopathic pulmonary fibrosis: challenges and opportunities, promises and pitfalls. Proc. Am. Thorac. Soc.3(4), 389–393 (2006).
   PubMedGoogle Scholar
• Freeburn RW, Armstrong L, Millar AB. Cultured alveolar macrophages from patients with idiopathic pulmonary fibrosis (IPF) show dysregulation of lipopolysaccharide-induced tumor necrosis factor-α (TNF-α) and interleukin-10 (IL-10) inductions. Eur. Cytokine Net.16(1), 5–16 (2005).
   PubMedGoogle Scholar
• Riha RL, Yang IA, Rabnott GC et al. Cytokine gene polymorphisms in idiopathic pulmonary fibrosis. Int. Med. J.34(3), 126–129 (2004).
   Google Scholar
• Uhal BD, Kim JK, Li X, Molina-Molina M. Angiotensin-TGF-β 1 crosstalk in human idiopathic pulmonary fibrosis: autocrine mechanisms in myofibroblasts and macrophages. Curr. Pharm. Des.13(12), 1247–1256 (2007).
   PubMed Web of Science ®Google Scholar
• Khalil N, Parekh TV, O’Connor R et al. Regulation of the effects of TGF-β 1 by activation of latent TGF-β 1 and differential expression of TGF-β receptors (T β R-I and T β R-II) in idiopathic pulmonary fibrosis. Thorax56(12), 907–915 (2001).
   PubMed Web of Science ®Google Scholar
• Tzortzaki EG, Antoniou KM, Zervou MI et al. Effects of antifibrotic agents on TGF-β1, CTGF and IFN-γ expression in patients with idiopathic pulmonary fibrosis. Resp. Med.101(8), 1821–1829 (2007).
   PubMed Web of Science ®Google Scholar
• Watts KL, Spiteri MA. Connective tissue growth factor expression and induction by transforming growth factor-β is abrogated by simvastatin via a Rho signaling mechanism. Am. J. Physiol. Lung Cell Mol. Physiol.287(6), L1323–L1332 (2004).
   PubMedGoogle Scholar
• Cao B, Guo Z, Zhu Y, Xu W. The potential role of PDGF, IGF-1, TGF-β expression in idiopathic pulmonary fibrosis. Chinese Med. J.113(9), 776–782 (2000).
   PubMedGoogle Scholar
• Homma S, Nagaoka I, Abe H et al. Localization of platelet-derived growth factor and insulin-like growth factor I in the fibrotic lung. Am. J. Resp. Crit. Care Med.152(6 Pt 1), 2084–2089 (1995).
   PubMed Web of Science ®Google Scholar
• Reichenberger F, Schauer J, Kellner K et al. Different expression of endothelin in the bronchoalveolar lavage in patients with pulmonary diseases. Lung179(3), 163–174 (2001).
   PubMed Web of Science ®Google Scholar
• Jain R, Shaul PW, Borok Z, Willis BC. Endothelin-1 induces alveolar epithelial–mesenchymal transition through endothelin type A receptor-mediated production of TGF-β1. Am. J. Resp. Cell Mol. Biol.37(1), 38–47 (2007).
   PubMed Web of Science ®Google Scholar
• Khalil N, Xu YD, O’Connor R, Duronio V. Proliferation of pulmonary interstitial fibroblasts is mediated by transforming growth factor-β1-induced release of extracellular fibroblast growth factor-2 and phosphorylation of p38 MAPK and JNK. J. Biol. Chem.280(52), 43000–43009 (2005).
   PubMed Web of Science ®Google Scholar
• Ye Q, Dalavanga Y, Poulakis N et al. Decreased expression of heme oxygenase-1 by alveolar macrophages in idiopathic pulmonary fibrosis. Eur. Respir. J. (2008).
   Google Scholar
• Englert JM, Hanford LE, Kaminski N et al. A role for the receptor for advanced glycation end products in idiopathic pulmonary fibrosis. Am. J. Pathol.172(3), 583–591 (2008).
   PubMed Web of Science ®Google Scholar
• Beeh KM, Beier J, Kornmann O, Buhl R. Neutrophilic inflammation in induced sputum of patients with idiopathic pulmonary fibrosis. Sarcoidosis Vasc. Diffuse Lung Dis.20(2), 138–143 (2003).
   PubMed Web of Science ®Google Scholar
• Knight DA, Ernst M, Anderson GP, Moodley YP, Mutsaers SE. The role of gp130/IL-6 cytokines in the development of pulmonary fibrosis: critical determinants of disease susceptibility and progression? Pharmacol. Ther.99(3), 327–338 (2003).
   PubMed Web of Science ®Google Scholar
• Hutyrova B, Pantelidis P, Drabek J et al. Interleukin-1 gene cluster polymorphisms in sarcoidosis and idiopathic pulmonary fibrosis. Am. J. Resp. Crit. Care Med.165(2), 148–151 (2002).
   PubMed Web of Science ®Google Scholar
• Vasakova M, Striz I, Slavcev A et al. Correlation of IL-1α and IL-4 gene polymorphisms and clinical parameters in idiopathic pulmonary fibrosis. Scand. J. Immunol.65(3), 265–270 (2007).
   PubMedGoogle Scholar
• Antoniou KM, Alexandrakis MG, Sfiridaki K et al. Th1 cytokine pattern (IL-12 and IL-18) in bronchoalveolar lavage fluid (BALF) before and after treatment with interferon γ-1b (IFN-γ-1b) or colchicine in patients with idiopathic pulmonary fibrosis (IPF/UIP). Sarcoidosis Vasc. Diffuse Lung Dis.21(2), 105–110 (2004).
   PubMed Web of Science ®Google Scholar
• Li JZ, Li ZH, Kang J, Hou XM, Yu RJ. [Change of prostaglandin E2 and interleukin-12, interleukin-13 in the bronchoalveolar lavage fluid and the serum of the patients with idiopathic pulmonary fibrosis]. Zhonghua Jie He He Hu Xi Za Zhi27(6), 378–380 (2004).
   PubMedGoogle Scholar
• Kitasato Y, Hoshino T, Okamoto M et al. Enhanced expression of interleukin-18 and its receptor in idiopathic pulmonary fibrosis. Am. J. Resp. Cell Mol. Biol.31(6), 619–625 (2004).
   PubMed Web of Science ®Google Scholar
• Lee CG, Cho SJ, Kang MJ et al. Early growth response gene 1-mediated apoptosis is essential for transforming growth factor b1-induced pulmonary fibrosis. J. Exp. Med.200(3), 377–389 (2004).
   PubMed Web of Science ®Google Scholar
• Zhang HY, Phan SH. Inhibition of myofibroblast apoptosis by transforming growth factor β1. Am. J. Resp. Cell Mol. Biol.21(6), 658–665 (1999).
   PubMed Web of Science ®Google Scholar
• Lee CG, Kang HR, Homer RJ, Chupp G, Elias JA. Transgenic modeling of transforming growth factor-β1: role of apoptosis in fibrosis and alveolar remodeling. Proc. Am. Thorac. Soc.3(5), 418–423 (2006).
   PubMedGoogle Scholar
• Reeves A, Zagurovskaya M, Gupta S et al. Inhibition of transforming growth factor-β signaling in normal lung epithelial cells confers resistance to ionizing radiation. Int. J. Radiation Oncol. Biol. Phys.68(1), 187–195 (2007).
   PubMedGoogle Scholar
• Allen JT, Knight RA, Bloor CA, Spiteri MA. Enhanced insulin-like growth factor binding protein-related protein 2 (connective tissue growth factor) expression in patients with idiopathic pulmonary fibrosis and pulmonary sarcoidosis. Am. J. Resp. Cell Mol. Biol.21(6), 693–700 (1999).
   PubMed Web of Science ®Google Scholar
• Bonner JC. Regulation of PDGF and its receptors in fibrotic diseases. Cytokine Growth Factor Rev.15(4), 255–273 (2004).
   PubMed Web of Science ®Google Scholar
• Ingram JL, Bonner JC. EGF and PDGF receptor tyrosine kinases as therapeutic targets for chronic lung diseases. Curr. Mol. Med.6(4), 409–421 (2006).
   PubMed Web of Science ®Google Scholar
• American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am. J. Resp. Crit. Care Med.161(2 Pt 1), 646–664 (2000).
   PubMed Web of Science ®Google Scholar
• Nathan SD. Therapeutic intervention: assessing the role of the international consensus guidelines. Chest128(5 Suppl. 1), 533S–539S (2005).
   PubMedGoogle Scholar
• Collard HR, Loyd JE, King TE Jr, Lancaster LH. Current diagnosis and management of idiopathic pulmonary fibrosis: a survey of academic physicians. Resp. Med.101(9), 2011–2016 (2007).
   PubMedGoogle Scholar
• Walter N, Collard HR, King TE Jr. Current perspectives on the treatment of idiopathic pulmonary fibrosis. Proc. Am. Thorac. Soc.3(4), 330–338 (2006).
   PubMedGoogle Scholar
• Daniels CE, Ryu JH. Treatment of idiopathic pulmonary fibrosis. Sem. Resp. Crit. Care Med.27(6), 668–676 (2006).
   PubMed Web of Science ®Google Scholar
• Horowitz JC, Thannickal VJ. Idiopathic pulmonary fibrosis: new concepts in pathogenesis and implications for drug therapy. Treat. Respir. Med.5(5), 325–342 (2006).
   PubMedGoogle Scholar
• Martinez FJ, Safrin S, Weycker D et al. The clinical course of patients with idiopathic pulmonary fibrosis. Ann. Intern. Med.142(12 Pt 1), 963–967 (2005).
   PubMed Web of Science ®Google Scholar
• Antoniu SA. Pirfenidone for the treatment of idiopathic pulmonary fibrosis. Expert Opin. Investig. Drugs15(7), 823–828 (2006).
   PubMed Web of Science ®Google Scholar
• Bouros D, Antoniou KM, Tzouvelekis A, Siafakas NM. Interferon-γ 1b for the treatment of idiopathic pulmonary fibrosis. Expert Opin. Biol. Ther.6(10), 1051–1060 (2006).
   PubMed Web of Science ®Google Scholar
• Thannickal VJ, Flaherty KR, Hyzy RC, Lynch JP 3rd. Emerging drugs for idiopathic pulmonary fibrosis. Expert Opin. Emerg. Drugs10(4), 707–727 (2005).
   PubMedGoogle Scholar
• Vuorinen K, Gao F, Oury TD, Kinnula VL, Myllarniemi M. Imatinib mesylate inhibits fibrogenesis in asbestos-induced interstitial pneumonia. Exp. Lung Res.33(7), 357–373 (2007).
   PubMed Web of Science ®Google Scholar
• Aono Y, Nishioka Y, Inayama M et al. Imatinib as a novel antifibrotic agent in bleomycin-induced pulmonary fibrosis in mice. Am. J. Resp. Crit. Care Med.171(11), 1279–1285 (2005).
   PubMed Web of Science ®Google Scholar
• Cohen MH, Johnson JR, Pazdur R. U.S. Food and Drug Administration Drug Approval Summary: conversion of imatinib mesylate (STI571; Gleevec) tablets from accelerated approval to full approval. Clin. Cancer Res.11(1), 12–19 (2005).
   PubMed Web of Science ®Google Scholar
• Deininger MW, Druker BJ. Specific targeted therapy of chronic myelogenous leukemia with imatinib. Pharmacol. Rev.55(3), 401–423 (2003).
   PubMed Web of Science ®Google Scholar
• Giles FJ, Cortes JE, Kantarjian HM. Targeting the kinase activity of the BCR–ABL fusion protein in patients with chronic myeloid leukemia. Curr. Mol. Med.5(7), 615–623 (2005).
   PubMed Web of Science ®Google Scholar
• Nagar B. c-Abl tyrosine kinase and inhibition by the cancer drug imatinib (Gleevec/STI-571). J. Nutr.137(6 Suppl. 1), 1518S–1523S (2007).
   PubMed Web of Science ®Google Scholar
• Ohno R. Treatment of chronic myeloid leukemia with imatinib mesylate. Int. J. Clin. Oncol.11(3), 176–183 (2006).
   PubMedGoogle Scholar
• Buchdunger E, Cioffi CL, Law N et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J. Pharmacol. Exp. Ther.295(1), 139–145 (2000).
   PubMed Web of Science ®Google Scholar
• Borg C, Terme M, Taieb J et al. Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects. J. Clin. Invest.114(3), 379–388 (2004).
   PubMed Web of Science ®Google Scholar
• Peng B, Lloyd P, Schran H. Clinical pharmacokinetics of imatinib. Clin. Pharmacokinet.44(9), 879–894 (2005).
   PubMed Web of Science ®Google Scholar
• Gschwind HP, Pfaar U, Waldmeier F et al. Metabolism and disposition of imatinib mesylate in healthy volunteers. Drug Metab. Dispos.33(10), 1503–1512 (2005).
   PubMed Web of Science ®Google Scholar
• le Coutre P, Kreuzer KA, Pursche S et al. Pharmacokinetics and cellular uptake of imatinib and its main metabolite CGP74588. Cancer Chemother. Pharmacol.53(4), 313–323 (2004).
   PubMed Web of Science ®Google Scholar
• Gibbons J, Egorin MJ, Ramanathan RK et al. Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of renal dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group. J. Clin. Oncol.26(4), 570–576 (2008).
   PubMed Web of Science ®Google Scholar
• Ramanathan RK, Egorin MJ, Takimoto CH et al. Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of liver dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group. J. Clin. Oncol.26(4), 563–569 (2008).
   PubMed Web of Science ®Google Scholar
• Yokoyama T, Miyazawa K, Kurakawa E et al. Interstitial pneumonia induced by imatinib mesylate: pathologic study demonstrates alveolar destruction and fibrosis with eosinophilic infiltration. Leukemia18(3), 645–646 (2004).
   PubMedGoogle Scholar
• Ohnishi K, Sakai F, Kudoh S, Ohno R. Twenty-seven cases of drug-induced interstitial lung disease associated with imatinib mesylate. Leukemia20(6), 1162–1164 (2006).
   PubMed Web of Science ®Google Scholar
• Chua F, Gauldie J, Laurent GJ. Pulmonary fibrosis: searching for model answers. Am. J. Resp. Cell Mol. Biol.33(1), 9–13 (2005).
   PubMed Web of Science ®Google Scholar
• Chaudhary NI, Schnapp A, Park JE. Pharmacologic differentiation of inflammation and fibrosis in the rat bleomycin model. Am. J. Resp. Crit. Care Med.173(7), 769–776 (2006).
   PubMed Web of Science ®Google Scholar
• Daniels CE, Wilkes MC, Edens M et al. Imatinib mesylate inhibits the profibrogenic activity of TGF-β and prevents bleomycin-mediated lung fibrosis. J. Clin. Invest.114(9), 1308–1316 (2004).
   PubMed Web of Science ®Google Scholar
• Li L, Li YQ. [Effect of imatinib mesylate on bleomycin-induced pulmonary fibrosis in mice]. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue19(4), 229–232 (2007).
   PubMedGoogle Scholar
• Vittal R, Zhang H, Han MK et al. Effects of the protein kinase inhibitor, imatinib mesylate, on epithelial/mesenchymal phenotypes: implications for treatment of fibrotic diseases. J. Pharmacol. Exp. Ther.321(1), 35–44 (2007).
   PubMed Web of Science ®Google Scholar
• Abdollahi A, Li M, Ping G et al. Inhibition of platelet-derived growth factor signaling attenuates pulmonary fibrosis. J. Exp. Med.201(6), 925–935 (2005).
   PubMed Web of Science ®Google Scholar
• Distler JH, Jungel A, Huber LC et al. Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. Arthritis Rheum.56(1), 311–322 (2007).
   PubMed Web of Science ®Google Scholar
• Yoshiji H, Kuriyama S, Noguchi R et al. Amelioration of liver fibrogenesis by dual inhibition of PDGF and TGF-β with a combination of imatinib mesylate and ACE inhibitor in rats. Int. J. Mol. Med.17(5), 899–904 (2006).
   PubMed Web of Science ®Google Scholar
• Nathan SD, Noble PW, Tuder RM. Idiopathic pulmonary fibrosis and pulmonary hypertension: connecting the dots. Am. J. Resp. Crit. Care Med.175(9), 875–880 (2007).
   PubMed Web of Science ®Google Scholar
• Nadrous HF, Pellikka PA, Krowka MJ et al. Pulmonary hypertension in patients with idiopathic pulmonary fibrosis. Chest128(4), 2393–2399 (2005).
   PubMed Web of Science ®Google Scholar
• Lettieri CJ, Nathan SD, Barnett SD, Ahmad S, Shorr AF. Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis. Chest129(3), 746–752 (2006).
   PubMed Web of Science ®Google Scholar
• Chaudhary NI, Roth GJ, Hilberg F et al. Inhibition of PDGF, VEGF and FGF signalling attenuates fibrosis. Eur. Respir. J.29(5), 976–985 (2007).
   PubMed Web of Science ®Google Scholar